HC Wainwright & Co. initiated coverage of AIkido Pharma with a rating of Buy and set a new price target of $2.00

New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company.  Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu's background broadens t

NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public.  AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00.  As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad

NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our

NEW YORK, Feb. 3, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Scott T. Tagawa, M.D., M.S., FACP, a Professor of Medicine and Urology at Weill Cornell Medicine and an Attending Physician at New York-Presbyterian-Weill Cornell Medical Center, has joined the Company's Scientific Advisory Board. "Scott is a leading scholar in the field of oncology medicine and research," commented Mr. Anthony Hayes, CEO of AIkido. "His experience and expertise will be of tremendous value as we further our efforts to develop therapeutic treatments for cancer and leverage the technologies we have licensed.  Dr. Tagawa is also the principle investi

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

4 - Dominari Holdings Inc. (0000012239) (Issuer)

8-K - Dominari Holdings Inc. (0000012239) (Filer)

8-K - Dominari Holdings Inc. (0000012239) (Filer)

10-Q - Dominari Holdings Inc. (0000012239) (Filer)

8-K - Dominari Holdings Inc. (0000012239) (Filer)

8-A12B - Dominari Holdings Inc. (0000012239) (Filer)

8-K - Dominari Holdings Inc. (0000012239) (Filer)

8-K - Dominari Holdings Inc. (0000012239) (Filer)

8-K - Dominari Holdings Inc. (0000012239) (Filer)

DEFA14A - Dominari Holdings Inc. (0000012239) (Filer)

DEF 14A - Dominari Holdings Inc. (0000012239) (Filer)

NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part

NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C

Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.    Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Excha

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on October 3, 2022, the Company purchased 45,000 shares of common stock at $6.98 per share. Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange A

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. The Company reported that on September 30, 2022, the Company purchased 41,096 shares of common stock at $ 7.1034 per share. Anthony Hayes, CEO of Aikido stated, "The Company's stock price is still below our book value, so we are continuing to allocate capital under our repurchase plan.  The board believes in the

NEW YORK, Sept. 30, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. In the framework of the Share Repurchase Program, the Company has repurchased 303,886 common shares in the period from January 21, 2022 up to and including September 29, 2022. The price per share range for the shares repurchased was $5.34 to $6.97. Additional shares may be repurchased from time to time in open

Acquisition Will Accelerate Growth Strategy NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ:AIKI) has entered into an exclusive agreement for the acquisition of a broker-dealer firm. This is Dominari's first acquisition since launching in June. Details of the proposed purchase can be found in the 8K on file with the SEC. Dominari Financial was formed with the intention of acquiring revenue generating assets in the fintech and financial services industry. "Our goal has always been to move swiftly to execute a roll-up strategy of wealth management firms that cater to ultra-high-net worth investors. This transfor

NEW YORK, Aug. 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash.  The Company's Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all AIkido shareholders. The Company will respond in due course.  There is no need for shareholders to take any action at this